|
|
|
| Webinar: Inside the Development of an AAV8 Production Platform Designed for Scale | Adeno-associated virus (AAV) vectors are pivotal in gene therapy, yet their production faces significant challenges, including scalability, low recovery rates, and the need for effective separation of empty and full capsids. This webinar presents a comprehensive AAV8 production platform developed together with CDMO Matica Biotechnology, and addresses industry pain points through innovative upstream and downstream processes. Click here to learn more. |
|
|
|
|
By Erin Harris, Editor-In-Chief, Cell & Gene | This summary of the Cell & Gene Live, Emerging Technologies in Cell Therapy Manufacturing, explains why automation, robotics, AI, and digital tools offer a clear path to scalable, efficient, and patient-centric manufacturing. | |
|
|
| Productivity Optimization For AAV Affinity Chromatography | Poster | By Alejandro Becerra-Arteaga, Ph.D., and Jett Appel, Thermo Fisher Scientific | In this work, dynamic binding capacity (DBC) data for multiple AAV serotypes were leveraged to estimate the optimal productivity of rAAV using the AAVX resin. |
|
|
|
| Cell Culture Process Scale-Up Challenges | White Paper | By Brian Lee, Sunghoon Jung, Yas Hashimura, et al., PBS Biotech, Inc. | Allogeneic cell therapies offer incredible promise, but scaling up PSC manufacturing presents unique challenges. Explore these hurdles along with solutions for consistent, high-quality production. |
|
|
|
|
| COGs Process Economics For Autologous Cell Therapy | White Paper | Cytiva | Analyze the cost distribution over time for autologous CAR T therapy manufacturing using process economics and additional insights. Discover how cell therapy manufacturers can combat these costs. |
|
|
|
|
|
|
| Webinar: Future-Proofing the Material Transfer Process in Your Facility with Automated Bio-decontamination | Developers of cell and gene therapies face challenges in safely transferring living materials into closed systems without contamination or damage. A robust material transfer program requires risk assessment and modern approaches, combining manual disinfection with automated bio-decontamination. This webinar explores how automated bio-decontamination systems can enhance material transfer processes, ensuring patient safety and regulatory compliance. Click here to learn more. |
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
